NYSE - Nasdaq Real Time Price USD

Globus Medical, Inc. (GMED)

51.74 +0.47 (+0.92%)
As of 10:50 AM EDT. Market Open.
Loading Chart for GMED
DELL
  • Previous Close 51.27
  • Open 51.08
  • Bid 51.83 x 800
  • Ask 51.84 x 800
  • Day's Range 51.19 - 51.99
  • 52 Week Range 43.39 - 62.88
  • Volume 109,922
  • Avg. Volume 1,044,946
  • Market Cap (intraday) 7.004B
  • Beta (5Y Monthly) 1.10
  • PE Ratio (TTM) 48.36
  • EPS (TTM) 1.07
  • Earnings Date May 2, 2024 - May 6, 2024
  • Forward Dividend & Yield --
  • Ex-Dividend Date --
  • 1y Target Est 61.46

Globus Medical, Inc., a medical device company, develops and commercializes healthcare solutions for patients with musculoskeletal disorders in the United States and internationally. The company offers spine products, such as traditional fusion implants comprising pedicle screw and rod systems, plating systems, intervertebral spacers, and corpectomy devices for treating degenerative and congenital conditions, deformity, tumors, and trauma injuries; treatment options for motion preservation technologies that consist of dynamic stabilization, total disc replacement, and interspinous distraction devices; interventional solutions to treat vertebral compression fractures; and regenerative biologic products comprising of allografts and synthetic alternatives. It also offers products for the treatment of orthopedic trauma, including fracture plates, compression screws, intramedullary nails, and external fixation systems; and hip and knee joint solutions, including modular hip stems and acetabular cups, as well as posterior stabilizing and cruciate retaining knee arthroplasty implants. In addition, the company distributes human cell, tissue, and cellular and tissue-based products. It sells its products through direct or distributor sales representatives, as well as hip and knee products through independent sales agents. Globus Medical, Inc. was incorporated in 2003 and is headquartered in Audubon, Pennsylvania.

www.globusmedical.com

5,000

Full Time Employees

December 31

Fiscal Year Ends

Recent News: GMED

Performance Overview: GMED

Trailing total returns as of 4/24/2024, which may include dividends or other distributions. Benchmark is

.

YTD Return

GMED
2.91%
S&P 500
6.30%

1-Year Return

GMED
10.67%
S&P 500
22.66%

3-Year Return

GMED
27.25%
S&P 500
21.29%

5-Year Return

GMED
14.24%
S&P 500
72.82%

Compare To: GMED

Select to analyze similar companies using key performance metrics; select up to 4 stocks.

Statistics: GMED

Valuation Measures

Annual
As of 4/23/2024
  • Market Cap

    6.94B

  • Enterprise Value

    6.94B

  • Trailing P/E

    47.92

  • Forward P/E

    19.08

  • PEG Ratio (5yr expected)

    1.74

  • Price/Sales (ttm)

    3.75

  • Price/Book (mrq)

    1.74

  • Enterprise Value/Revenue

    4.43

  • Enterprise Value/EBITDA

    20.03

Financial Highlights

Profitability and Income Statement

  • Profit Margin

    7.83%

  • Return on Assets (ttm)

    4.77%

  • Return on Equity (ttm)

    4.21%

  • Revenue (ttm)

    1.57B

  • Net Income Avi to Common (ttm)

    122.87M

  • Diluted EPS (ttm)

    1.07

Balance Sheet and Cash Flow

  • Total Cash (mrq)

    517.79M

  • Total Debt/Equity (mrq)

    13.04%

  • Levered Free Cash Flow (ttm)

    -346.92M

Research Analysis: GMED

Analyst Price Targets

25.00 Low
61.46 Average
51.74 Current
83.00 High
 

Analyst Recommendations

  • Strong Buy
  • Buy
  • Hold
  • Underperform
  • Sell
 

Earnings

Consensus EPS
 

Company Insights: GMED

Fair Value

51.74 Current
 

Dividend Score

0 Low
GMED
Sector Avg.
100 High
 

Hiring Score

0 Low
GMED
Sector Avg.
100 High
 

Insider Sentiment Score

0 Low
GMED
Sector Avg.
100 High
 

Research Reports: GMED

  • GMED: Lowering target price to $41.00

    GLOBUS MEDICAL INC - A has an Investment Rating of SELL; a target price of $41.000000; an Industry Subrating of Low; a Management Subrating of Low; a Safety Subrating of Medium; a Financial Strength Subrating of Low; a Growth Subrating of Low; and a Value Subrating of Medium.

    Rating
    Price Target
     
  • GMED: Raising target price to $43.00

    GLOBUS MEDICAL INC - A has an Investment Rating of SELL; a target price of $43.000000; an Industry Subrating of Low; a Management Subrating of Low; a Safety Subrating of Medium; a Financial Strength Subrating of Low; a Growth Subrating of Low; and a Value Subrating of Medium.

    Rating
    Price Target
     
  • GMED: What does Argus have to say about GMED?

    GLOBUS MEDICAL INC - A has an Investment Rating of SELL; a target price of $41.000000; an Industry Subrating of Low; a Management Subrating of Low; a Safety Subrating of Medium; a Financial Strength Subrating of Low; a Growth Subrating of Low; and a Value Subrating of Medium.

    Rating
    Price Target
     
  • GMED: Lowering target price to $41.00

    GLOBUS MEDICAL INC - A has an Investment Rating of SELL; a target price of $41.000000; an Industry Subrating of Low; a Management Subrating of Low; a Safety Subrating of Medium; a Financial Strength Subrating of Low; a Growth Subrating of Low; and a Value Subrating of Medium.

    Rating
    Price Target
     

People Also Watch